- Home
- COCH vs BLRX Comparison
COCH vs BLRX Comparison
Compare COCH & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COCH
- BLRX
- Stock Information
- Founded
- COCH 1995
- BLRX 2003
- Country
- COCH United States
- BLRX Israel
- Employees
- COCH N/A
- BLRX N/A
- Industry
- COCH Blank Checks
- BLRX Biotechnology: Pharmaceutical Preparations
- Sector
- COCH Finance
- BLRX Health Care
- Exchange
- COCH Nasdaq
- BLRX Nasdaq
- Market Cap
- COCH 19.2M
- BLRX 17.1M
- IPO Year
- COCH N/A
- BLRX 2011
- Fundamental
- Price
- COCH $0.91
- BLRX $3.88
- Analyst Decision
- COCH Strong Buy
- BLRX Strong Buy
- Analyst Count
- COCH 2
- BLRX 2
- Target Price
- COCH $9.25
- BLRX $19.00
- AVG Volume (30 Days)
- COCH 8.4M
- BLRX 51.9K
- Earning Date
- COCH 11-13-2025
- BLRX 11-24-2025
- Dividend Yield
- COCH N/A
- BLRX N/A
- EPS Growth
- COCH N/A
- BLRX N/A
- EPS
- COCH N/A
- BLRX N/A
- Revenue
- COCH $222,000.00
- BLRX $17,251,000.00
- Revenue This Year
- COCH $3.66
- BLRX N/A
- Revenue Next Year
- COCH $31.19
- BLRX N/A
- P/E Ratio
- COCH N/A
- BLRX N/A
- Revenue Growth
- COCH N/A
- BLRX 1.19
- 52 Week Low
- COCH $0.74
- BLRX $2.30
- 52 Week High
- COCH $3.09
- BLRX $22.60
- Technical
- Relative Strength Index (RSI)
- COCH 47.04
- BLRX 46.83
- Support Level
- COCH $0.87
- BLRX $3.57
- Resistance Level
- COCH $1.02
- BLRX $4.56
- Average True Range (ATR)
- COCH 0.11
- BLRX 0.33
- MACD
- COCH 0.03
- BLRX 0.01
- Stochastic Oscillator
- COCH 19.16
- BLRX 28.71
About COCH Envoy Medical Inc.
Envoy Medical Inc is a hearing health company focused on providing medical technologies. It is dedicated to pushing hearing technology beyond the status quo to provide patients with improved access, usability, independence and quality of life. The Company has one reportable segment: hearing. The hearing segment derives revenue from the sale of the Esteem FI-AMEI implants and replacement components to Esteem FI-AMEI implants.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.